Expert Perspectives on the Updated ACC Decision Pathway for Optimization of Heart Failure Treatment

home / peers-and-perspective / expert-perspectives-on-the-updated-acc-decision-pathway-for-optimization-of-heart-failure-treatment

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, review recent updates in the recommendations for optimal medical care for patients with heart failure with reduced ejection fraction.

Diagnosis of Heart Failure (HF)

EP. 1: Diagnosis of Heart Failure (HF)

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
March 26th 2021

Javed Butler, MD, MPH, MBA, discusses the staging and difficulties associated with diagnosing heart failure.

Watch

Role of Early Treatment and Gaps in Heart Failure Diagnosis

EP. 2: Role of Early Treatment and Gaps in Heart Failure Diagnosis

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
March 26th 2021

The role of early aggressive treatment in preventing progression of heart failures and the importance of understanding the root cause of disease.

Watch

Heart Failure Treatment in the Healthcare System

EP. 3: Heart Failure Treatment in the Healthcare System

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 2nd 2021

A look into the role of heart failure treatment in health care and the overall provision of optimal medical therapy.

Watch

ACC Expert Consensus Decision Pathway for HF Treatment

EP. 4: ACC Expert Consensus Decision Pathway for HF Treatment

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 2nd 2021

Using the ACC Expert Consensus Decision Pathway documents for the optimization of heart failure treatment and managing the increasing complexity of the disease.

Watch

Evolution of Heart Failure Treatments 

EP. 5: Evolution of Heart Failure Treatments 

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 9th 2021

Experts in cardiology provide a brief history on treatments used for heart failure including ACE (angiotensin converting enzyme) inhibitors and beta blockers.

Watch

Using Sacubitril/Valsartan in Heart Failure Treatment 

EP. 6: Using Sacubitril/Valsartan in Heart Failure Treatment 

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 9th 2021

A discussion on the safety and efficacy of angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, for the treatment of heart failure.

Watch

Considering ARNIs as De Novo Therapy in Heart Failure

EP. 7: Considering ARNIs as De Novo Therapy in Heart Failure

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 16th 2021

Considerations for initiating sacubitril/valsartan as de novo therapy in patients naïve to angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapies as per the 2021 update of the expert consensus decision pathway document.

Watch

Target Dose in HF Therapies for Reduced Ejection Fraction

EP. 8: Target Dose in HF Therapies for Reduced Ejection Fraction

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 16th 2021

Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.

Watch

Role of MRA Blockers in HF Treatment

EP. 9: Role of MRA Blockers in HF Treatment

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 23rd 2021

Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.

Watch

Evolution of SGLT2 Inhibitors in Treatment Regimens

EP. 10: Evolution of SGLT2 Inhibitors in Treatment Regimens

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 23rd 2021

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.

Watch

Role of SGLT2 Inhibitor Therapy for HF Treatment

EP. 11: Role of SGLT2 Inhibitor Therapy for HF Treatment

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 30th 2021

Insights on approaching the initiation of SGLT2 inhibitors for the treatment of heart failure with reduced ejection fraction.

Watch

Challenges for Achieving Optimal Therapy in HF

EP. 12: Challenges for Achieving Optimal Therapy in HF

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
April 30th 2021

Cardiology experts discuss challenges in achieving the optimal therapy for patients with heart failure and the influence of patient lifestyle and medical factors.

Watch

Emerging Agents for Heart Failure Treatment

EP. 13: Emerging Agents for Heart Failure Treatment

James Januzzi, MD, Massachusetts General Hospital, Harvard Medical School;Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center
May 7th 2021

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.

Watch

© 2024 MJH Life Sciences

All rights reserved.